Letrozol Teva

Letrozole, the active ingredient in Letrozol Teva, is a aromatase inhibitor presented as a tablet for oral use. It is indicated for the treatment of hormone receptor‑positive breast cancer in postmenopausal women, including adjuvant and advanced disease settings.

GNH USA supplies Letrozol Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Letrozol Teva is an aromatase inhibitor used in the management of hormone‑dependent breast cancer. It works by reducing estrogen production, which slows tumor growth.

- Adjuvant treatment of early‑stage hormone receptor‑positive breast cancer in postmenopausal women: helps prevent disease recurrence after surgery. - First‑line therapy for advanced or metastatic hormone receptor‑positive breast cancer in postmenopausal women: slows disease progression. - Extended adjuvant therapy after five years of tamoxifen in postmenopausal women: reduces risk of late recurrence.

Letrozol Teva may cause a range of adverse reactions, from mild to severe. Patients should be monitored regularly for any new symptoms.

Common Side Effects: - Hot flashes: transient increase in body temperature. - Joint and muscle pain: arthralgia or myalgia. - Fatigue: general feeling of tiredness. - Nausea: mild gastrointestinal upset. - Headache: occasional mild to moderate pain. - Increased cholesterol: elevation of serum lipid levels.

Serious or Rare Side Effects: - Osteoporosis or bone fractures: decreased bone mineral density. - Severe liver injury: marked elevation of transaminases. - Deep vein thrombosis or pulmonary embolism: clot formation. - Cardiovascular events: hypertension or myocardial infarction. - Allergic reactions: rash, pruritus, or anaphylaxis. - Vision changes: blurred vision or ocular disturbances.

Before initiating Letrozol Teva, clinicians should assess patient risk factors and monitor relevant parameters. - Bone health assessment: baseline DEXA scan and periodic monitoring. - Liver function monitoring: check transaminases before and during therapy. - Lipid profile evaluation: assess cholesterol levels regularly. - Cardiovascular risk review: monitor blood pressure and cardiac status. - Pregnancy contraindication: avoid use in pregnant or nursing women; effective contraception required. - Store at ambient temperature: keep below 25°C, retain in original packaging, protect from moisture and direct sunlight.

Letrozol Teva can interact with several medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Strong CYP2A6 inhibitors (e.g., ketoconazole): may increase letrozole plasma levels. - Estrogen‑containing hormone therapy: antagonizes therapeutic effect. - Live vaccines: reduced immune response due to hormonal modulation.

Moderate Interactions (Monitor Closely): - Cholesterol‑lowering agents (e.g., statins): may require lipid monitoring. - Anticoagulants (e.g., warfarin): monitor INR for potential changes. - Antidepressants (SSRIs): observe for additive fatigue or mood effects.